SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq ...

BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gatherin ...

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company extends through 2027.Transaction projected to close in the first half of 2026. The comb ...

~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in its Phase 2 EXPLORE-OSA trial of lorundrostat ...

GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its recently launched bfPREP ...

CALGARY, Alberta, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Karbon-X Corp. (OTCQX: KARX), a leader in end-to-end climate solutions, is advancing the development of the Alberta Solar Rewards Program in partnership with an Alberta-based solar provider. The initiative is designed to enable homeowners with rooftop solar systems to generate verified carbon credits under Alberta’s Technology Innovation and Emissions Reduction (TIER) framework. The initiative addresses a longstanding gap in the regulated carbon market, w ...

VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), toda ...

Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as well as insured ...

~ Delivers 1H25 Free Cash Flow Growth of 16%, Reinforcing SaaS Model’s Efficiency ~ ~ Recurring Revenue Now 92.2% of Total Revenues, Firmly Establishing the Nuvini as a Pure Play SaaS Company ~ ~ Churn Continues on Successful Downward Trend ~ ~ Nuvini CEO Pierre Schurmann to Host Investor Webinar on Tuesday, September 30th, 2025 at 10:00a.m. Eastern Time ~ NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), the leading serial acquirer and operator o ...

VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LEEF Brands, Inc. (CSE: LEEF, OTCQB: LEEEF) (“LEEF” or the “Company”), a premier multi-state operator, is pleased to announce that its extraction lab in Upstate New York is now operational. The Company has completed installation of its equipment and has commenced solventless concentrate production, with hydrocarbon capabilities expected to come online next quarter. This positions LEEF to meet rising demand in one of the U.S.’s fastest-growing c ...